Short Interest in Pharming Group (NASDAQ:PHAR) Decreases By 48.8%

Pharming Group (NASDAQ:PHAR) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 10,400 shares, a decrease of 48.8% from the November 30th total of 20,300 shares. Based on an average daily trading volume, of 7,400 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Oppenheimer decreased their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Jefferies Financial Group began coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, December 17th.

Pharming Group Trading Down 6.3 %

Shares of PHAR traded down $0.62 during mid-day trading on Friday, reaching $9.93. 991 shares of the company were exchanged, compared to its average volume of 5,273. The business has a 50 day simple moving average of $8.45 and a two-hundred day simple moving average of $8.20. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20. The stock has a market capitalization of $673.60 million, a PE ratio of -38.19 and a beta of 0.05. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.